Oncogenic activation of the phosphatidylinositol-3-kinase (PI3K), protein kinase B (PKB-AKT), and mammalian target of rapamycin (mTOR) pathway is a frequent event in prostate cancer that facilitates tumor formation, disease progression and therapeutic resistance. This evidence concerns the gene AKT1 and prostate cancer.